Assenagon Asset Management
RVMD icon

Assenagon Asset Management’s Revolution Medicines RVMD Stock Holding History

Assenagon Asset Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$448M Buy
2,181,185
+1,980,699
+988% +$393M 0.43% 41
2026
Q2 		$37.5M Buy
+200,486
New +$29.3M 0.05% 289

Other funds holding RVMD

Chicago Capital
Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return
LPPL
Loftus Peak Pty Ltd Sydney, Australia $781M AUM
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
Wedmont Private Capital
Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return
IFM Investors
IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Gateway Investment Advisers
Gateway Investment Advisers Cincinnati, Ohio $11B AUM 34.31% 1-Year Est. Return
Atria Investments
Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
First Citizens Bank & Trust
First Citizens Bank & Trust Raleigh, North Carolina $6.73B AUM 18.92% 1-Year Est. Return

Assenagon Asset Management's RVMD Position: Q3 2026 in Review

Assenagon Asset Management increased its Revolution Medicines (RVMD) stake by 988% in Q3 2026, buying an estimated $393M and bringing the position to 2,181,185 shares worth $448M. The position accounts for 0.43% of the portfolio, ranked #41.

Assenagon Asset Management first reported a position in RVMD in Q2 2026 and has held it in 2 quarters since. 61 funds tracked by Wall St. Rank hold RVMD as of Q3 2026.

  • Assenagon Asset Management held 2,181,185 shares of Revolution Medicines worth $448M as of Q3 2026.
  • Assenagon Asset Management bought 1,980,699 Revolution Medicines shares in Q3 2026, an estimated $393M.
  • Revolution Medicines made up 0.43% of Assenagon Asset Management's portfolio in Q3 2026, its #41 holding.
  • Assenagon Asset Management first reported a position in Revolution Medicines in Q2 2026 and has held it in 2 quarters since.
  • 61 funds tracked by Wall St. Rank held Revolution Medicines as of Q3 2026.

Based on Assenagon Asset Management's 13F filing for Q3 2026, filed 15 Oct 2026.